Diana Cuervo

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry

Pau Montesinos, Gaspar Aspas Requena, Eliana Aguiar, Joana Brioso et autres

es, fr, br, pt, co, ar, uy, cl, mx, bo (code pays fourni par la source)

Real-world insights into acquired aplastic anemia: the Latin American Registry of Aplastic Anemia

Virginia Abello Polo, Gabriela Vidal‐Senmache, Vera Milovic, Alejandra La Torre-Matuk et autres

Aplastic anemia (AA) is a rare condition characterized by bone marrow hypocellularity and pancytopenia, with a global prevalence of 2 cases per million individuals per year. The Latin American Registry of Aplastic Anemia was established in 2017 to evaluate the prevalence, clinical …

co, pe, ar, ve, uy, es, br (code pays fourni par la source)

Non-coding RNAs as mediators of tyrosine kinase inhibitor resistance in chronic myeloid leukemia: a scoping review

Diana Cuervo, Alexander Casallas Vega

Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry

Jorge Labrador, David Martínez‐Cuadrón, Cristina Gil, Josefina Serrano et autres

Abstract Introduction: Most patients with acute myeloid leukemia (AML) who receive palliative best supportive care (BSC) alone experience poor outcomes, with reported median overall survival (OS) below two months. However, a subset of these patients not deemed for active therapy may survive …

es, pt, cl, co (code pays fourni par la source)

Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry

Jorge Labrador, David Martínez‐Cuadrón, Cristina Gil, Josefina Serrano et autres

Abstract Background: The therapeutic landscape of acute myeloid leukemia (AML) has evolved substantially over the past three decades. While intensive chemotherapy (IC) was the mainstay until the mid-2000s, the advent of hypomethylating agents (HMA), venetoclax-based regimens, and targeted therapies (e.g., FLT3 or …

es, pt, cl, co (code pays fourni par la source)

Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy

Bruno Paiva, Leire Burgos, Carmen González, Rebeca Rodriguez Veiga et autres

Abstract Background: Despite advances in treatment of AML pts considered fit for intensive therapy, significant unmet medical needs remain. Early end points for survival can accelerate the approval of novel therapies. MRD has been recently accepted as an early end point in …

es, gb, cl, co, pt, uy (code pays fourni par la source)

Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

Ana Alfonso Piérola, David Martínez‐Cuadrón, Rebeca Rodríguez‐Veiga, Cristina Gil et autres

While allogeneic stem cell transplantation (allo-SCT) is the preferred consolidation for high and most intermediate-risk acute myeloid leukemia (AML) patients in first remission, the role of autologous SCT (auto-SCT) vs. chemotherapy (CT) when allo-SCT is not feasible or indicated, remains controversial. We …

es, cl, co, uy (code pays fourni par la source)

Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study

Claudia Sossa, Virginia Abello Polo, Luis Antonio Salazar, Ángela María Peña et autres

There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, …

co, es (code pays fourni par la source)

Descripción de una serie de casos de trombocitopenias de origen genético diagnosticadas en el servicio de Hematología del Hospital de San José entre los años 2000-2021 y revisión narrativa de la literatura

Claudia Patricia Casas Patarroyo, María Helena Solano Trujillo, Gerson Menoyo-Caballero, María Lorcy Monsalve-Córdoba et autres

Introducción: las trombocitopenias genéticas (TG) son un grupo de enfermedades clásicamente consideradas raras, asociadas a sangrado grave y restringidas a la población pediátrica. Objetivos: describir los casos de trombocitopenias genéticas atendidos en el servicio de Hematología del Hospital de San José durante …

co (code pays fourni par la source)

Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry

Virginia Abello Polo, Claudia Sossa, Carla Boquimpani, Luis Antonio Salazar et autres

BACKGROUND: Chronic myeloid leukemia (CML) treatment has significantly evolved with the introduction of tyrosine kinase inhibitors. However, access to these treatments and outcomes vary globally. This study examines 2 decades of CML management in Colombia using the RENEHOC registry, focusing on TKI …

us, co, br, es (code pays fourni par la source)

Clinical Features and Prognostic Factors in Multiple Myeloma Patients from Colombia. Real-World Data from Renehoc Registry

Julian Pedraza, Sossa-Melo Claudia, Diana Cuervo, Humberto Martínez‐Cordero et autres

Background: The prognosis for patients with multiple myeloma (MM) has improved over time, but there is considerable heterogeneity in disease outcomes. Currently used risk models have been validated using data from patients in clinical trials, but their applicability to real-world populations may …

co (code pays fourni par la source)

Comparison of the Revised 4 Th (2016) and 5 Th (2022) Editions of the World Health Organization (WHO) Classification in a Cohort of Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms (MDS) - a Glam Registry (REGLAM) Analysis

Marcelo Iastrebner, Amer M. Zeidan, Jorge Arbelbide, Elvira Deolinda Rodrigues Pereira Velloso et autres

Background: The5 th (2022) edition of the WHO Classification for MDS recognizes MDS patients into two groups: MDS with defining genetic abnormalities and MDS morphologically defined. Further, the revised International Prognostic Scoring system (IPSS-R) assigns MDS patients into one of prognostic groups …

us, ar, br, uy, co, mx, cl (code pays fourni par la source)